Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)

{ 'indexed': {'date-parts': [[2024, 3, 26]], 'date-time': '2024-03-26T21:51:53Z', 'timestamp': 1711489913784}, 'reference-count': 29, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 9, 1]], 'date-time': '2023-09-01T00:00:00Z', 'timestamp': 1693526400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 6, 20]], 'date-time': '2023-06-20T00:00:00Z', 'timestamp': 1687219200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ { 'DOI': '10.13039/100016175', 'name': 'Chulabhorn Royal Academy', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'ijidonline.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 9]]}, 'DOI': '10.1016/j.ijid.2023.06.018', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 30]], 'date-time': '2023-06-30T06:07:12Z', 'timestamp': 1688105232000}, 'page': '211-219', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': 'Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to ' 'prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized ' 'controlled trial (EFFaCo study)', 'prefix': '10.1016', 'volume': '134', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7256-9982', 'authenticated-orcid': False, 'given': 'Taweegrit', 'family': 'Siripongboonsitti', 'sequence': 'first', 'affiliation': []}, {'given': 'Teerapat', 'family': 'Ungtrakul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kriangkrai', 'family': 'Tawinprai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tararin', 'family': 'Nimmol', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mullika', 'family': 'Buttakosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gaidganok', 'family': 'Sornsamdang', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Tanadul', 'family': 'Jarrusrojwuttikul', 'sequence': 'additional', 'affiliation': []}, {'given': 'Phumin', 'family': 'Silapant', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nithi', 'family': 'Mahanonda', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ijid.2023.06.018_bib0001', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0002', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0003', 'unstructured': 'United States Food and Drug Administration, FDA Network of European ' 'World Shops. RELEASE, coronavirus (COVID-19) update: FDA authorizes ' 'first oral antiviral for treatment of COVID-19, ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19; ' '2021 [accessed 22 December 2021].'}, { 'key': '10.1016/j.ijid.2023.06.018_sbref0004', 'series-title': 'Clinical practice guideline to diagnosis, treatment and prevention ' 'COVID-19 for Physicain and health care provider', 'year': '2021'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '11022', 'DOI': '10.1038/s41598-021-90551-6', 'article-title': 'Martinez-de-Hoyo R. The efficacy and safety of favipiravir in treatment ' 'of COVID-19: a systematic review and meta-analysis of clinical trials', 'volume': '11', 'author': 'Hassanipour', 'year': '2021', 'journal-title': 'Sci Rep'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.1186/s12985-020-01412-z', 'article-title': 'Favipiravir versus other antiviral or standard of care for COVID-19 ' 'treatment: a rapid systematic review and meta-analysis', 'volume': '17', 'author': 'Shrestha', 'year': '2020', 'journal-title': 'Virol J'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0007', 'doi-asserted-by': 'crossref', 'first-page': 'e432', 'DOI': '10.1093/cid/ciab962', 'article-title': 'Efficacy of early treatment with favipiravir on disease progression ' 'among high-risk patients with coronavirus disease 2019 (COVID-19): a ' 'randomized, open-label clinical trial', 'volume': '75', 'author': 'Chuah', 'year': '2022', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '242', 'DOI': '10.1002/cpt.1844', 'article-title': 'Favipiravir: pharmacokinetics and concerns about clinical trials for ' '2019-nCoV infection', 'volume': '108', 'author': 'Du', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0009', 'doi-asserted-by': 'crossref', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', 'volume': '93', 'author': 'Furuta', 'year': '2017', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0010', 'first-page': '1192', 'article-title': 'Experimental treatment with favipiravir for COVID-19: an open-label ' 'control study', 'volume': '6', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering (Beijing)'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0011', 'article-title': 'Favipiravir versus arbidol for clinical recovery rate in moderate and ' 'severe adult COVID-19 patients: a prospective, multicenter, open-label, ' 'randomized clinical trial', 'volume': '12', 'author': 'Chen', 'year': '2021', 'journal-title': 'Front Pharmacol'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '531', 'DOI': '10.1093/cid/ciaa1176', 'article-title': 'AVIFAVIR for treatment of patients with moderate coronavirus disease ' '2019 (COVID-19): interim results of a Phase II/III multicenter ' 'randomized clinical trial', 'volume': '73', 'author': 'Ivashchenko', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0013', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2021.652688', 'article-title': 'Fluvoxamine: a review of its mechanism of action and its role in ' 'COVID-19', 'volume': '12', 'author': 'Sukhatme', 'year': '2021', 'journal-title': 'Front Pharmacol'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0014', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.106044', 'article-title': 'Widely available lysosome targeting agents should be considered as ' 'potential therapy for COVID-19', 'volume': '56', 'author': 'Homolak', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0015', 'doi-asserted-by': 'crossref', 'first-page': '34', 'DOI': '10.1016/j.virol.2019.05.002', 'article-title': 'The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy ' 'induction in cells infected with coronavirus infectious bronchitis ' 'virus', 'volume': '533', 'author': 'Fung', 'year': '2019', 'journal-title': 'Virology'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '149', 'DOI': '10.2165/00129784-200303030-00001', 'article-title': 'Effect of selective serotonin reuptake inhibitors on platelet ' 'activation: can they prevent acute myocardial infarction?', 'volume': '3', 'author': 'Schlienger', 'year': '2003', 'journal-title': 'Am J Cardiovasc Drugs'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0017', 'doi-asserted-by': 'crossref', 'first-page': '2292', 'DOI': '10.1001/jama.2020.22760', 'article-title': 'Fluvoxamine vs placebo and clinical deterioration in outpatients with ' 'symptomatic COVID-19: a randomized clinical trial', 'volume': '324', 'author': 'Lenze', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0018', 'doi-asserted-by': 'crossref', 'first-page': '1315', 'DOI': '10.4269/ajtmh.21-1310', 'article-title': 'Fluvoxamine for the early treatment of COVID-19: a meta-analysis of ' 'randomized clinical trials', 'volume': '106', 'author': 'Guo', 'year': '2022', 'journal-title': 'Am J Trop Med Hyg'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0019', 'doi-asserted-by': 'crossref', 'first-page': 'e42', 'DOI': '10.1016/S2214-109X(21)00448-4', 'article-title': 'Effect of early treatment with fluvoxamine on risk of emergency care ' 'and hospitalisation among patients with COVID-19: the TOGETHER ' 'randomised, platform clinical trial', 'volume': '10', 'author': 'Reis', 'year': '2022', 'journal-title': 'Lancet Glob Health'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '667', 'DOI': '10.7326/M22-3305', 'article-title': 'Oral fluvoxamine with inhaled budesonide for treatment of early-onset ' 'COVID-19: a randomized platform trial', 'volume': '176', 'author': 'Reis', 'year': '2023', 'journal-title': 'Ann Intern Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0021', 'doi-asserted-by': 'crossref', 'first-page': 'ofab050', 'DOI': '10.1093/ofid/ofab050', 'article-title': 'Prospective cohort of fluvoxamine for early treatment of coronavirus ' 'Disease 19', 'volume': '8', 'author': 'Seftel', 'year': '2021', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0022', 'doi-asserted-by': 'crossref', 'unstructured': 'McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, ' 'et\xa0al. Fluvoxamine for outpatient treatment of COVID-19: a ' 'decentralized, placebo-controlled, randomized, platform clinical trial. ' 'medRxiv. 01 November 2022. ' 'https://www.medrxiv.org/content/10.1101/2022.10.17.22281178 [accessed 2 ' 'November 2022].', 'DOI': '10.1093/ofid/ofac492.1881'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0023', 'doi-asserted-by': 'crossref', 'first-page': '599', 'DOI': '10.1056/NEJMoa2201662', 'article-title': 'Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19', 'volume': '387', 'author': 'Bramante', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0024', 'doi-asserted-by': 'crossref', 'first-page': '389', 'DOI': '10.18071/isz.74.0389', 'article-title': 'Fluoxetine use is associated with improved survival of patients with ' 'COVID-19 pneumonia: a retrospective case-control study', 'volume': '74', 'author': 'Németh', 'year': '2021', 'journal-title': 'Ideggyogy Sz'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '56', 'DOI': '10.1016/j.bpsgos.2021.12.007', 'article-title': 'Risk of death in individuals hospitalized for COVID-19 with and without ' 'psychiatric disorders: an observational multicenter study in France', 'volume': '3', 'author': 'Hoertel', 'year': '2023', 'journal-title': 'Biol Psychiatry Glob Open Sci'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0026', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2021.33090', 'article-title': 'Mortality risk among patients with COVID-19 prescribed selective ' 'serotonin reuptake inhibitor antidepressants', 'volume': '4', 'author': 'Oskotsky', 'year': '2021', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0027', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2022.6269', 'article-title': 'Fluvoxamine for outpatient management of COVID-19 to prevent ' 'hospitalization: a systematic review and meta-analysis', 'volume': '5', 'author': 'Lee', 'year': '2022', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0028', 'doi-asserted-by': 'crossref', 'first-page': '102', 'DOI': '10.3947/ic.2021.0142', 'article-title': 'Fluvoxamine treatment of patients with symptomatic COVID-19 in a ' 'community treatment center: a preliminary result of randomized ' 'controlled trial', 'volume': '54', 'author': 'Seo', 'year': '2022', 'journal-title': 'Infect Chemother'}, { 'key': '10.1016/j.ijid.2023.06.018_bib0029', 'doi-asserted-by': 'crossref', 'first-page': '1629', 'DOI': '10.1016/S1473-3099(21)00685-X', 'article-title': 'Increased risk of hospitalisation and death with the delta variant in ' 'the USA', 'volume': '21', 'author': 'Bast', 'year': '2021', 'journal-title': 'Lancet Infect Dis'}], 'container-title': 'International Journal of Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971223006410?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971223006410?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 10, 13]], 'date-time': '2023-10-13T19:14:19Z', 'timestamp': 1697224459000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1201971223006410'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 9]]}, 'references-count': 29, 'alternative-id': ['S1201971223006410'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2023.06.018', 'relation': {}, 'ISSN': ['1201-9712'], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'International Journal of Infectious Diseases', 'published': {'date-parts': [[2023, 9]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir ' 'monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 ' 'patients: Open-label randomized controlled trial (EFFaCo study)', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'International Journal of Infectious Diseases', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ijid.2023.06.018', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2023 The Author(s). Published by Elsevier Ltd on behalf of International ' 'Society for Infectious Diseases.', 'name': 'copyright', 'label': 'Copyright'}]}